Open AccessImpact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
Author(s) -
Douglas Mark W.,
Tay Enoch S.E.,
Wang Dao Sen,
Ong Adrian T.L.,
Wilson Caroline,
Phu Amy,
Kok Jen,
Dwyer Dominic E.,
Bull Rowena A.,
Lloyd Andrew R.,
Applegate Tanya L.,
Dore Gregory J.,
Howe Anita Y.,
Harrigan Richard,
George Jacob
Publication year - 2020
Publication title -
hepatology communications
Language(s) - English
Resource type - Journals
ISSN - 2471-254X
DOI - 10.1002/hep4.1496
Subject(s) - ns5a , sofosbuvir , ns5b , ns3 , hepatitis c virus , genotype , drug resistance , virology , regimen , medicine , daclatasvir , population , telaprevir , simeprevir , ribavirin , pharmacology , biology , virus , hepacivirus , microbiology and biotechnology , genetics , gene , environmental health
Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real‐world studies are needed to inform the impact of widespread DAA treatment on antiviral resistance in the community. The prevalence and range of posttreatment resistance‐associated substitutions (RASs) was determined in Australian patients with open access to DAAs through a wide range of prescribers. NS3, NS5A, and NS5B regions were amplified by polymerase chain reaction and analyzed by population sequencing. Clinically relevant RASs were identified using online databases (ReCALL and Geno2Pheno[hcv]). Of 572 samples, 60% were from genotype 3 and 27% from genotype 1a. Ninety‐two percent of people failed a DAA regimen containing an NS5A inhibitor, including 10% with a pangenotype regimen. NS5A RASs were detected in 72% of people with genotype 1 and 80% with genotype 3. For genotype 1, there was a range of RASs across the NS5A region, while for genotype 3, the Y93H RAS predominated (72%). The prevalence of NS3 RASs was higher in people exposed to an NS3 inhibitor (35% vs. 3.9%; P < 0.0001). NS5B resistance was rare, with a single case of sofosbuvir resistance. Multiclass drug resistance was found in 33% of people exposed to both NS3 and NS5A inhibitors. Conclusion : The high prevalence of NS5A RASs among people failing DAA therapy reinforces the importance of specific retreatment regimens, ideally guided by resistance testing. The impact of multiclass drug resistance on retreatment in people exposed to both NS3 and NS5A inhibitors needs to be assessed in real‐world studies. Surveillance for increasing antiviral resistance during treatment scale‐up is essential to maintain the efficacy of current DAA regimens.